Ziprasidone

/Ziprasidone
Ziprasidone 2020-07-11T20:20:16+08:00

Ziprasidone

Ziprasidone (CP-88059) 是 5-HT 和多巴胺 (dopamine receptor) 受体拮抗剂,具有抗精神病活性,用于多种精神疾病,如精神分裂症。

中文名:齐拉西酮

英文名:Ziprasidone; CP-88059

CAS 号: 146939-27-7

分子式:C21H21ClN4OS

分子量:412.94

纯度:>98.0%

DescriptionZiprasidone (CP-88059) is a combined 5-HT (serotonin) and dopamine receptor antagonist. Ziprasidone exhibits potent effects of antipsychotic activity, and is used for treating various mental disorders including schizophrenia[1][2][3].
In VitroZiprasidone possesses an in vitro 5-HT2A/dopamine D2 receptor affinity ratio higher than any clinically available antipsychotic agent. In vivo, ziprasidone antagonizes 5-HT2A receptor-induced head twitch with 6-fold higher potency than for blockade of d-amphetamine-induced hyperactivity, a measure of central dopamine D2 receptor antagonism. Ziprasidone also has high affinity for the 5-HT1A, 5-HT1D and 5-HT2C receptor subtypes, which may further enhance its therapeutic potential[1].
Ziprasidone sulfoxide and sulfone were the major metabolites in human serum. The affinities of the sulfoxide and sulfone metabolites for 5-HT2 and D2 receptors are low with respect to ziprasidone, and are thus unlikely to contribute to its antipsychotic effects[2].
Ziprasidone was associated with significant differential adverse effects relative to placebo in BPM, BPD, and schizophrenia with no significant difference in weight gain in all 3 groups. Self-reported somnolence was increased across the 3 conditions. Subjects with BPM were more vulnerable to EPS than those with BPD or schizophrenia[3].
References[1]. Seeger, T.F., et al., Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther, 1995. 275(1): p. 101-13.

[2]. Prakash, C., et al., Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metab Dispos, 1997. 25(7): p. 863-72.

[3]. Gao, K., et al., Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia. J Clin Psychopharmacol, 2013. 33(3): p. 425-31.

电子邮箱
  • enquiry@bestbiochem.com
QQ客服
  • 1652852700 点击这里给我发消息
技术转让
  • 医药化工类技术转让平台